Multiple sclerosis / palavik

In vivo models for rabGEF1-dependent signaling and functions

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

BACKGROUND OF THE INVENTION Mast cells are major effector cells for immediate hypersensitivity and allergic diseases. In these settings, mast cell activation by IgE antibody and antigen contributes to pathology, such as in anaphylaxis, asthma, hay fever and atopic dermatitis or eczema. Activation of

Imidazole-containing peptides having immunomodulatory activity

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

FIELD OF THE INVENTION This invention relates to novel imidazole-containing peptides and processes for preparation thereof. BACKGROUND OF THE INVENTION It is known that N-acetyl-L-phenylalanyl-L-phenylalanyl-L-histidine methyl ester shows anti-gastric and anti-ulcer activity (U.S. Pat. No.

Hydrazine derivatives

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

BACKGROUND OF THE INVENTION Release of such cytokines as tumor necrosis factor .alpha.(TNF-.alpha.) and transforming growth factor .alpha.(TGF-.alpha.) can cause adverse reactions ranging from fever to sepsis. Many of these reactions are related to inflammation or autoinmuune conditions, such as

Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and TACE inhibitors

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

FIELD OF INVENTION This invention relates to allenic aryl sulfonamide hydroxamic acids which act as inhibitors of TNF-.alpha. converting enzyme (TACE) and matrix metalloproteinase (MMP). The compounds of the present invention are useful in disease conditions mediated by MMP and TACE, such as

Pyrimidine compounds and their uses

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

FIELD Described are novel heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof. ##STR00002## The present invention also

Pyrimidine compounds and their uses

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

FIELD Described are novel heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof. ##STR00002## The present invention also

Heterocycles

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

FIELD Described are novel heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof. The present invention more particularly

Substituted heterocyclic compounds and methods of use

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

BACKGROUND OF THE INVENTION The present invention comprises a new class of compounds useful in treating diseases, such as TNF-.alpha., IL-1.beta., IL-6 and/or IL-8 mediated diseases and other maladies, such as pain and diabetes. In particular, the compounds of the invention are useful for the

Substituted heterocyclic compounds and methods of use

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

BACKGROUND OF THE INVENTION The present invention comprises a new class of compounds useful in treating diseases, such as TNF-.alpha., IL-1.beta., IL-6 and/or IL-8 mediated diseases and other maladies, such as pain and diabetes. In particular, the compounds of the invention are useful for the

Pyrimidine carboxamides

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

FIELD OF THE INVENTION The present invention relates to novel compounds of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmaceutically acceptable salts and compositions, their

Substituted heterocyclic compounds and methods of use

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

BACKGROUND OF THE INVENTION The present invention comprises a new class of compounds useful in treating diseases, such as TNF-.alpha., IL-1.beta., IL-6 and/or IL-8 mediated diseases and other maladies, such as pain and diabetes. In particular, the compounds of the invention are useful for the

Substituted heterocyclic compounds and methods of use

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

BACKGROUND OF THE INVENTION The present invention comprises a new class of compounds useful in treating diseases, such as TNF-.alpha., IL-1.beta., IL-6 and/or IL-8 mediated diseases and other maladies, such as pain and diabetes. In particular, the compounds of the invention are useful for the

Substituted heterocyclic compounds and methods of use

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

BACKGROUND OF THE INVENTION The present invention comprises a new class of compounds useful in treating diseases, such as TNF-.alpha., IL-1.beta., IL-6 and/or IL-8 mediated diseases and other maladies, such as pain and diabetes. In particular, the compounds of the invention are useful for the

Interleukin-2 stimulated T lymphocyte cell death for the treatment of autoimmune diseases, allergic responses, and graft rejection

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to the treatment and prevention of diseases that are primarily due to T cell immune responses. In particular, it relates to the suppression or elimination of certain autoimmune diseases, graft rejection, and allergic

multiple sclerosis/palavik

In vivo models for rabGEF1-dependent signaling and functions

Imidazole-containing peptides having immunomodulatory activity

Hydrazine derivatives

Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and TACE inhibitors

Pyrimidine compounds and their uses

Pyrimidine compounds and their uses

Heterocycles

Substituted heterocyclic compounds and methods of use

Substituted heterocyclic compounds and methods of use

Pyrimidine carboxamides

Substituted heterocyclic compounds and methods of use

Substituted heterocyclic compounds and methods of use

Substituted heterocyclic compounds and methods of use

Interleukin-2 stimulated T lymphocyte cell death for the treatment of autoimmune diseases, allergic responses, and graft rejection

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus